Literature DB >> 25682109

The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence.

A Karl1, A Buchner, C Tympner, T Kirchner, U Ganswindt, C Belka, R Ganzer, M Burger, F Eder, F Hofstädter, D Schilling, K Sievert, A Stenzl, M Scharpf, F Fend, F Vom Dorp, H Rübben, K Schmid, D Porres-Knoblauch, A Heidenreich, B Hangarter, R Knüchel-Clarke, M Rogenhofer, B Wullich, A Hartmann, E Comploj, A Pycha, E Hanspeter, D Pehrke, G Sauter, M Graefen, C Stief, A Haese.   

Abstract

PURPOSE: To predict biochemical recurrence respecting the natural course of pT2 prostate cancer with positive surgical margin (R1) and no adjuvant/neoadjuvant therapy.
METHODS: A multicenter data analysis of 956 patients with pT2R1N0/Nx tumors was performed. Patients underwent radical prostatectomy between 1994 and 2009. No patients received neoadjuvant or adjuvant therapy. All prostate specimens were re-evaluated according to a well-defined protocol. The association of pathological and clinical features, in regard to BCR, was calculated using various statistical tests.
RESULTS: With a mean follow-up of 48 months, BCR was found in 25.4 %. In univariate analysis, multiple parameters such as tumor volume, PSA, Gleason at positive margin were significantly associated with BCR. However, in multivariate analysis, Gleason score (GS) of the prostatectomy specimen was the only significant parameter for BCR. Median time to recurrence for GS ≤ 6 was not reached; 5-year BCR-free survival was 82 %; and they were 127 months and 72 % for GS 3+4, 56 months and 54 % for GS 4 + 3, and 27 months and 32 % for GS 8-10. The retrospective approach is a limitation of our study.
CONCLUSIONS: Our study provides data on the BCR in pT2R1-PCa without adjuvant/neoadjuvant therapy and thus a rationale for an individual's risk stratification. The data support patients and physicians in estimating the individual risk and timing of BCR and thus serve to personalize the management in pT2R1-PCa.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25682109     DOI: 10.1007/s00345-015-1510-y

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  24 in total

Review 1.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

Authors:  D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

Review 2.  Radiotherapy after prostatectomy: is the evidence for dose escalation out there?

Authors:  Christopher R King; Daniel S Kapp
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-01-30       Impact factor: 7.038

3.  Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10.

Authors:  Manfred Sassowsky; Philipp Gut; Tobias Hölscher; Guido Hildebrandt; Arndt-Christian Müller; Yousef Najafi; Götz Kohler; Helmut Kranzbühler; Matthias Guckenberger; Daniel R Zwahlen; Ngwa C Azinwi; Ludwig Plasswilm; Istvan Takacs; Christiane Reuter; Marcin Sumila; Peter Manser; Piet Ost; Dirk Böhmer; Christiane Pilop; Daniel M Aebersold; Pirus Ghadjar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-08-22       Impact factor: 7.038

4.  Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.

Authors:  Alberto Briganti; Thomas Wiegel; Steven Joniau; Cesare Cozzarini; Marco Bianchi; Maxine Sun; Bertrand Tombal; Karin Haustermans; Tom Budiharto; Wolfgang Hinkelbein; Nadia Di Muzio; Pierre I Karakiewicz; Francesco Montorsi; Hein Van Poppel
Journal:  Eur Urol       Date:  2012-05-16       Impact factor: 20.096

5.  Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.

Authors:  Jeff M Michalski; Colleen Lawton; Issam El Naqa; Mark Ritter; Elizabeth O'Meara; Michael J Seider; W Robert Lee; Seth A Rosenthal; Thomas Pisansky; Charles Catton; Richard K Valicenti; Anthony L Zietman; Walter R Bosch; Howard Sandler; Mark K Buyyounouski; Cynthia Ménard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-23       Impact factor: 7.038

6.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

7.  Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.

Authors:  Gregory P Swanson; Michael A Hussey; Catherine M Tangen; Joseph Chin; Edward Messing; Edith Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

8.  Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality.

Authors:  Andrew J Stephenson; Scott E Eggener; Adrian V Hernandez; Eric A Klein; Michael W Kattan; David P Wood; Danny M Rabah; James A Eastham; Peter T Scardino
Journal:  Eur Urol       Date:  2013-08-27       Impact factor: 20.096

9.  Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.

Authors:  Johnny Ray Bernard; Steven J Buskirk; Michael G Heckman; Nancy N Diehl; Stephen J Ko; Orlan K Macdonald; Steven E Schild; Thomas M Pisansky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-21       Impact factor: 7.038

Review 10.  Early salvage radiotherapy following radical prostatectomy.

Authors:  David Pfister; Michel Bolla; Alberto Briganti; Peter Carroll; Cesare Cozzarini; Steven Joniau; Hein van Poppel; Mack Roach; Andrew Stephenson; Thomas Wiegel; Michael J Zelefsky
Journal:  Eur Urol       Date:  2013-08-15       Impact factor: 20.096

View more
  9 in total

1.  Management of low- and intermediate-risk prostate cancer.

Authors:  Henk van der Poel; Laurence Klotz; Christian G Stief
Journal:  World J Urol       Date:  2015-07       Impact factor: 4.226

2.  [Active surveillance of low risk prostate cancer].

Authors:  L Weißbach
Journal:  Urologe A       Date:  2015-06       Impact factor: 0.639

3.  Intraoperative frozen section monitoring during nerve-sparing radical prostatectomy: evaluation of partial secondary resection of neurovascular bundles and its effect on oncologic and functional outcome.

Authors:  Georgios Hatzichristodoulou; Stefan Wagenpfeil; Gregor Weirich; Michael Autenrieth; Tobias Maurer; Mark Thalgott; Thomas Horn; Matthias Heck; Kathleen Herkommer; Jürgen E Gschwend; Hubert Kübler
Journal:  World J Urol       Date:  2015-06-23       Impact factor: 4.226

4.  [Advanced Prostate Cancer Consensus Conference 2017 : Discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts].

Authors:  M Schostak; F König; M Bögemann; P Goebell; P Hammerer; S Machtens; C Schwentner; C Thomas; G von Amsberg; F-C von Rundstedt; A Heidenreich
Journal:  Urologe A       Date:  2018-07       Impact factor: 0.639

5.  Extended versus limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: long-term results and trifecta rates of a comparative analysis.

Authors:  Georgios Hatzichristodoulou; Stefan Wagenpfeil; Gudrun Wagenpfeil; Tobias Maurer; Thomas Horn; Kathleen Herkommer; Marie Hegemann; Jürgen E Gschwend; Hubert Kübler
Journal:  World J Urol       Date:  2015-09-29       Impact factor: 4.226

6.  [Gap between postulated and real outcome quality of radical prostatectomy].

Authors:  C Hampel; F Roos; J W Thüroff; A Neisius
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

7.  [Active surveillance for low-risk prostate cancer].

Authors:  Annika Herlemann; Christian G Stief
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

8.  The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features: An updated PRISMA-compliant systematic review and meta-analysis.

Authors:  Wei Jiang; Lijin Zhang; Bin Wu; Zhenlei Zha; Hu Zhao; Yuan Jun; Yuefang Jiang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

9.  Biochemical recurrence of pathological T2+ localized prostate cancer after robotic-assisted radical prostatectomy: A 10-year surveillance.

Authors:  Che Hseuh Yang; Yi Sheng Lin; Yen Chuan Ou; Wei Chun Weng; Li Hua Huang; Chin Heng Lu; Chao Yu Hsu; Min Che Tung
Journal:  World J Clin Cases       Date:  2021-02-16       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.